Analysts fell to the sidelines weighing in on Sumitomo Dainippon Pharma Co (DNPUF – Research Report) and Sanofi (SNYNF – Research Report) with ...
A new international biotech – Sumitovant Biopharma – has been created after Sumitomo Dainippon’s strategic alliance with Roivant Sciences came to fruition as 2019 drew to a close.
日经225指数 中表现最好的股票为Sumitomo Dainippon Pharma Co Ltd (TYO: 4506 ),上涨9.72%(69.00点),收盘报价为779.00。同时,住友电工 (TYO: 5802 ...
日经225指数 中表现最好的股票为Sumitomo Dainippon Pharma Co Ltd (TYO: 4506 ),上涨16.39%(100.00点),收盘报价为710.00。同时,Konami Corp. (TYO: 9766 ...
Ltd. The company has a strategic alliance with Roivant Sciences Ltd. The company was formerly known as Sumitomo Dainippon Pharma Co., Ltd. and changed its name to Sumitomo Pharma Co., Ltd.
Sumitomo Dainippon Pharma Co Ltd (TYO:4506)下跌2.51%(9.00点),收于349.00;CyberAgent Inc (TYO:4751)收盘时跌2.33%(24.50点),报价1,029.00。 东京证券交易所0只个股 ...
Sumitomo already held around 52% of the company ahead of the new offer – which values Myovant at around $2.9 billion – and is spending $1.7 billion to gain 100% ownership of its shares.